US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: BiBBInstruments CEO: “First order sends positive signals”

For BiBBInstruments, 2024 revolved around clinical evaluation. The company is now kicking off the new year with its first order for EndoDrill GI, from US clinic UC Davis Health. BioStock reached out to CEO Fredrik Lindblad to learn more about this commercial milestone.Read the interview at biostock.se : https://www.biostock.se/en/2025/01/bibbinstruments-ceo-first-order-sends-positive-signals/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BiBB receives first order for EndoDrill GI from a university hospital in the US

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of EndoDrill[®], the world's first market-cleared, electric-driven biopsy instrument for endoscopy, announces that the first order for EndoDrill[® ]GI has been received from the university hospital UC Davis Health in the USA. This initial order has a small order value but holds great significance, as UC Davis Health becomes BiBB's first paying customer."It feels fantastic to now have our first customer in the USA, and the order is proof that we have developed an innovative biopsy product that benefits

BiBBInstruments announces final outcome of rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. BiBBInstruments AB (“BiBB” or the “Company”) today announces the final outcome of the rights issue of units of approximately SEK 36.5 million that was

BiBBInstruments announces preliminary outcome of rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. BiBBInstruments AB (“BiBB” or the “Company”) today announces the preliminary outcome of the rights issue of units of approximately SEK 36.5 million that

Clinical evaluation at Karolinska University Hospital is progressing

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of EndoDrill[®], the world's first market-cleared, electric-driven biopsy instrument for endoscopy, announces that the Company's clinical evaluation is proceeding at Karolinska University Hospital in Stockholm. During the Company's visit to the hospital, Dr. Fredrik Swahn performed biopsy sampling using EndoDrill[® ]GI on three patients with suspected pancreatic tumors, resulting in visible core biopsies in all cases. The hospital was provided with more disposable instruments to complete the evaluation.

BioStock: BiBBInstrument’ founder on the Sahlgrenska evaluation

BiBBInstruments takes another step in the clinical evaluation of EndoDrill GI. Recently, Sahlgrenska University Hospital in Gothenburg joined the growing group of clinics evaluating the instrument. BioStock contacted the company’s founder and CMO Charles Walther to get his thoughts.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/bibbinstrument-founder-on-the-sahlgrenska-evaluation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Well-executed clinical introduction of EndoDrill[®] GI at Sahlgrenska University Hospital in Sweden

The cancer diagnostics company BiBBInstruments AB ("BiBB" and the “Company”), the developer of EndoDrill[®], the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first clinical tissue sampling procedures with EndoDrill[® ]GI at Sahlgrenska University Hospital in Gothenburg have been successfully completed. Expanded market studies at several hospitals in Europe and the USA are an important part of the Company's strategy and represent the first step in the launch of EndoDrill[®] GI.“It was very rewarding to be present and witness users from yet

BiBB has initiated a collaboration with Swedish contract manufacturer Cenova

The cancer diagnostics company BiBBInstruments AB ("BiBB" and the “Company”), the developer of EndoDrill[®], the world's first market-cleared electric-driven biopsy instrument for endoscopy, informs that the Company has initiated a collaboration with the Swedish contract manufacturer Cenova. The transfer of the production of disposable instruments to Cenova is planned to be completed by mid-2025. This enables a quality-assured production tailored for commercial volumes, which is a requirement from potential distribution partners”With the plans for strategic collaboration with one or more

BiBBInstrument’s CEO to BioStock: “Distributors are contacting us”

BiBBInstruments recently released its report for the third quarter and at the same time announced a rights issue of approximately SEK 36.5 million. BioStock contacted CEO Fredrik Lindblad to learn more.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/bibbinstruments-ceo-distributors-are-contacting-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Impressive US Clinical Case Series presented at ACG 2024 in Philadelphia

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that a recently published clinical case series in the U.S. has been presented at a poster session at the ACG 2024 in Philadelphia, USA. The study outcome demonstrated 100 % diagnostic accuracy after a single needle puncture, and the authors conclude that the EndoDrill[®] GI has great potential to be implemented as a first option in any scenario where endoscopic ultrasound (EUS)-guided tissue acquisition is

BiBB receives an Intention to Grant for EndoDrill patent in China

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from the China National Intellectual Property Administration (CNIPA). The notice means that CNIPA intends to approve a patent application for EndoDrill[®] in the first patent family in China. Certain formalities will now follow before approval, after which the patent will be valid until October 2039.BiBB has received an Intention to Grant from CNIPA regarding the

New Peer-Reviewed Clinical Case Series in the U.S. Shows 100% Diagnostic Accuracy with EndoDrill GI

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first eight patient cases using EndoDrill[®] GI in the U.S. have been scientifically published in Endoscopy International Open. Biopsies were sampled in the pancreas, esophagus, stomach, and small intestine. In all cases EndoDrill[® ]GI obtained 100% diagnostic accuracy after only one needle pass. In four patients, both EndoDrill[® ]GI and conventional needles were used to sample the same lesion, in

BioStock: BiBB comments on the growing interest in EndoDrill GI

Intensive work is underway to get EndoDrill GI out to European and US clinics. BiBBInstruments recently participated in the seventh edition of the Nordic EUS Meeting in Copenhagen, where the biopsy instrument aroused great interest. BioStock has spoken to CEO Fredrik Lindblad to learn more.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/bibb-comments-on-the-growing-interest-in-endodrill-gi/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

EndoDrill GI sparks interest at the 7th Nordic EUS Meeting in Copenhagen

The cancer diagnostics company BiBBInstruments AB ("BiBB or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the Company, for the first time, has exhibited a commercial version of EndoDrill[®] GI at the 7th Nordic EUS Meeting in Copenhagen. The meeting was aimed at BiBB’s target group, EUS endoscopists, and several participants expressed interest in the EndoDrill[®] technology. Demonstrations of the EndoDrill[®] GI system resulted in explicit requests to clinically evaluate the product from several new hospitals

BiBB’s CEO to BioStock: “Zagreb confirms good samples and short learning curve”

The clinical introduction is in full swing for BiBBInstruments. The company’s first electric-driven biopsy instrument, EndoDrill GI, continues to impress with high-quality tissue samples, most recently at an introduction of EndoDrill GI at the University Hospital in Zagreb. Meanwhile, the European Patent Office announced the intention to grant the patent application for the EndoDrill technology. BioStock spoke to BiBB’s CEO Fredrik Lindblad to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/bibbs-ceo-zagreb-confirms-

BiBB receives an Intention to Grant for EndoDrill patent in Europe

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from the European Patent Office (EPO). The notice means that the EPO intends to approve a divisional patent application (first patent family) in Europe for EndoDrill[®]. Certain formalities will now follow before approval, after which the patent will be valid until October 2039.BIBB has received an Intention to Grant from the EPO regarding the approval of the patent

Successful introduction of EndoDrill GI at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, announces that the University Hospital Center Sestre Milosrdnice in Zagreb, Croatia, has started a clinical evaluation with EndoDrill[®] GI. This makes the hospital the first in southern Europe to test EndoDrill[®] GI. Dr. Tajana Pavic, Head of Interventional Gastroenterology Unit, performed the patient cases.The EndoDrill[®] GI instrument provided high-quality core tissue biopsies in all four patient cases, including three solid

BioStock: BiBBInstruments’ technology gets nod in medical journal

The interest in Swedish medtech BiBBInstruments’ biopsy instrument EndoDrill is increasing as doctors evaluate it in the clinic, being called a “game-changer” within endoscopic ultrasound. Recently, the technology was also featured in a South American medical journal Revista de Gastroenterología del Perú, penned by leading specialist in the field, Dr Antonio Mendoza Ladd.Read the article at biostock.se: BiBBInstruments’ technology gets nod in medical journal - BioStock This is a press release

EndoDrill is recognized as a promising new product for solving a significant clinical problem in a medical journal

The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of EndoDrill[®], the world's first market-cleared motorized endoscopic core biopsy instrument, informs that EndoDrill[®] is recognized as a promising new EUS product on the editorial page of the South American medical journal Revista de Gastroenterología del Perú."It is encouraging that EndoDrill[®] is recognized as a promising new EUS instrument in an editorial that describes the future of endoscopic ultrasound. In addition, by an endoscopist who has recently tested the product clinically”, says Dr Charles Walther,

BioStock: Interest in BiBBInstruments’ EndoDrill GI continues to increase

The world's first market-cleared electric-driven biopsy instrument for endoscopy, EndoDrill GI, continues its track record of successful clinical evaluations. The device has received high praise from physicians at the University Hospital in Örebro and Haukeland University Hospital in Bergen, Norway. –  We notice that the interest in EndoDrill GI is gradually increasing as we initiate evaluations at new hospitals and participate in congresses, says Fredrik Lindblad, CEO at BiBB.Read the article at biostock.se: Interest in BiBBInstruments’ EndoDrill GI continues to increase - BioStock (

BiBBInstruments AB carries out a directed share issue of SEK 10.0 million

The Board of Directors of the cancer diagnostics company BiBBInstruments AB (publ) ("BiBB" or the "Company") has, based on the authorization granted by the Annual General Meeting on 14 June 2023, resolved to carry out a directed share issue of approximately SEK 10.0 million directed to existing major shareholders. Existing owners include Tibia Konsult, Swedencare Entrepreneurs, the Aktia Nordic Micro Cap fund, and Herenco Group owner Lovisa Hamrin. The net proceeds will primarily be used for continued clinical evaluation of EndoDrill[®] GI in the USA and Europe, as well as for preparations

Successful case studies with EndoDrill GI continue in Norway and Sweden

The cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, informs that clinical evaluation with EndoDrill[®] GI has started at two additional hospitals in Scandinavia. Several patient cases have been successfully performed at Haukeland University Hospital in Bergen, Norway, as well as at the University Hospital in Örebro. This means that EndoDrill[®] GI is now being evaluated in Sweden (Karolinska University Hospital and Örebro University Hospital), Norway (Haukeland

BioStock: EndoDrill seen as promising new EUS technology

BiBBInstruments’ endoscopic ultrasound instrument EndoDrill GI was recognised as a “New Kid on the Block” at the ESGE Days conference, indicating its emergence as a promising technology in the EUS field, challenging traditional methods of endoscopic tissue sampling. BioStock spoke with BiBB’s CEO Fredrik Lindblad to get his reaction to the conference.Read the article at biostock.se: EndoDrill seen as promising new EUS technology - BioStock This is a press release from BioStock - Connecting Innovation &

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe